

**EISAI CO., LTD.
AND
CONSOLIDATED SUBSIDIARIES
QUARTERLY FINANCIAL REPORT RELEASE**

**FOR IMMEDIATE RELEASE
February 2, 2006**

On February 2, 2006, Eisai Co., Ltd. announced quarterly consolidated financial results for the fiscal year ending March 31, 2006.

- Eisai Co., Ltd. is listed on the First Section of both the Tokyo Stock Exchange and the Osaka Securities Exchange.
- Securities Code Number: 4523
- Representative of corporation: Haruo Naito
Director, President & CEO
- Inquiries should be directed to: Hiroyuki Mitsui
Vice President
Corporate Communications

4-6-10 Koishikawa, Bunkyo-ku
Tokyo 112-8088, Japan

1. CONSOLIDATED THIRD QUARTER FINANCIAL RESULTS (October 1, 2005 – December 31, 2005)

1. NOTES TO PREPARATION OF THIRD QUARTER FINANCIAL REPORT

- (1) There have been no changes in accounting methods used by Eisai Co., Ltd. and its consolidated entities (hereinafter referred to as ‘the Company’) during the quarterly period.
- (2) Changes in the number of consolidated subsidiaries and associated companies accounted for by the equity method.

Number of newly consolidated subsidiaries: 2 (Eisai Pharma AG and Eisai AB)

Number of companies omitted from consolidation: 1 (Weizai Co., Ltd.)

2. CONSOLIDATED FINANCIAL RESULTS FOR THE THIRD QUARTER OF THE FISCAL YEAR ENDING MARCH 31, 2006

(1) RESULTS OF OPERATIONS

<Third Quarter>

Period	Net Sales	Percent Change	Operating Income	Percent Change	Ordinary Income	Percent Change

Period	Net Income	Percent Change	Earnings per Share (EPS)	Fully Diluted EPS
October 1, 2005-				

All figures less than 1,000,000 yen have been omitted.

(2) FINANCIAL POSITION

Period End	Total Assets	Shareholders' Equity	Shareholders' Equity to Total Assets	Shareholders' Equity per Share
December 31, 2005	¥712,055 mil.	¥505,238 mil.	71.0%	¥1,767.63
December 31, 2004	¥661,329 mil.	¥445,505 mil.	67.4%	¥1,558.89
March 31, 2005	¥662,711 mil.	¥459,607 mil.	69.4%	¥1,608.22

(3) CASH FLOW CONDITION**<Third Quarter>**

Period	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Cash Equivalents
October 1, 2005- December 31, 2005	¥9,212 mil.	(¥10,099 mil.)	(¥11,737 mil.)	¥150,165 mil.
October 1, 2004- December 31, 2004	¥12,240 mil.	(¥8,056 mil.)	(¥12,242 mil.)	¥152,620 mil.

<Nine Months>

Period End	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Cash Equivalents
December 31, 2005	¥49,116 mil.	(¥24,235 mil.)	(¥21,864 mil.)	¥150,165 mil.
December 31, 2004	¥53,022 mil.	(¥29,552 mil.)	(¥16,852 mil.)	¥152,620 mil.
March 31, 2005	¥49,200 mil.	(¥37,531 mil.)	(¥16,743 mil.)	¥142,429 mil.

All figures less than 1,000,000 yen have been omitted.

<Nine Months>

Period	Net Sales	Percent Change	Operating Income	Percent Change
--------	-----------	----------------	------------------	----------------

All figures less than 1,000,000 yen have been omitted.

[Third Quarter Financial Highlights] (October 1, 2005 – December 31, 2005)

- ' Consolidated net sales during the quarter amounted to ¥167,280 million which was a 16.6% increase compared to the corresponding period last year.
- ' With regard to consolidated net sales of major products, sales of *Aricept*, an Alzheimer's disease treatment, soared to ¥52,734 million, a 15.4% rise year-on-year. Out of this gain, sales of ¥12,086 million were attributed to Japan, up 22.1% and those of ¥31,628 million were recorded in North America, up 15.7%. (5.6% up on a dollar-denominated basis) Sales of *Pariet* (U.S. brand name: *Aciphex*), a proton pump inhibitor, totaled ¥42,439 million with an increase of 17.9%. While sales in Japan rose 29.8% to ¥8,513 million, those in North America inched up 12.7% (a 2.3% increase on a dollar-denominated basis) to ¥30,767 million.
- ' With respect to net sales to external customers by each geographic area, Japanese sales secured a 12.0% gain and the North American market expanded 20.4% while the European territories gained ground by 14.9% and 'Asian and other markets' augmented 63.3% on a year-on-year basis respectively.
- ' Cost of goods sold increased 18.7% to ¥29,973 million with the sales cost ratio being 17.9%, an increase of 0.3 percentage points from the previous-year period. And research and development (R&D) expenses came to ¥22,628 million, up 15.8% from a year earlier period while selling, general and administrative expenses amounted to ¥81,729 million, up 13.6%.
- ' When it comes to earnings results, operating income for the quarter advanced 23.4% year-on-year to ¥32,949 million; ordinary income rose 29.0% to ¥34,316 million; and net income in the third quarter ascended 33.3% to ¥21,997 million. Earnings per share (EPS) came to ¥76.96, a ¥19.42 rise from the corresponding period last year.
- ' Net cash provided by operating activities in the quarter was ¥9,212 million, decrease of ¥3,028 million on a year-on-year basis. Cash outflows arising from investing activities totaled ¥10,099 million, up

Ordinary income: ¥81,415 million (16.6% increase year-on-year)

Net income: ¥52,156 million (18.4% increase year-on-year)

' Net sales of *Aricept* increased by 16.9% year-on-year to ¥142,625 million and those of *Aciphex/Pariet*

¥84,206 million (an increase of 3.0% on a dollar-denominated basis).

Europe:

- 1 Sales in Europe climbed 11.9% to ¥32,857 million and operating income came to ¥3,396 million, up 38.0%.
- 1 Sales of *Aricept* increased 6.9% to ¥22,621 million and those of *Pariet* rose 8.2% to ¥5,615 million partly attributable to the initiation of operation in Italy.

Asia and other regions:

- 1 Sales in Asia and other regions amounted to ¥12,557 million, up 45.9%, and operating income increased to ¥2,192 million, up 19.4%.
- 1 Sales of *Aricept* grew 50.7% to ¥3,144 million, and sales of *Pariet* surged 63.6% to ¥2,523 million respectively.

Overseas total:

- 1 Total overseas sales, excluding Japan, advanced 15.4% to ¥229,095 million, accounting for 50.9% of the Company's consolidated net sales, which is an increase by 1.8 percentage points from the previous-year period.

[Cash flow]

- 1 Net cash generated by operating activities during the nine months under review decreased to ¥49,116 million, down ¥3,905 million from the corresponding period of the preceding year. Income before income taxes amounted to ¥80,996 million and depreciation and amortization expenses came to ¥18,546 million while income taxes paid totaled ¥41,435 million.
- 1 Cash outflows arising from investing activities totaled ¥24,235 million, down ¥5,317 million year-on-year, out of which ¥18,356 million was used for the procurement of property, plant and equipment and ¥13,244 million for the purpose of purchasing intangible fixed assets.
- 1 Net cash used in financing activities including but not limited to payment for dividends amounted to ¥21,864 million, a year-on-year increase of ¥5,012 million.
- 1 As a result of such operating, investing and financing activities, cash and cash

[For reference]

(Outlook of non-consolidated financial performance)

- 1 The financial forecast on a non-consolidated basis for the full fiscal year ending March 31, 2006 was also revised upward from what was previously announced in October 2005 as follows:

	Revised Forecast	Previous Forecast	Increase/ Decrease	Changes	
	(A) YOY(%)	(B)	(A-B)	(%)	

EISAI CO., LTD.

1-1) CONSOLIDATED BALANCE SHEET (ASSETS)

Account Title	March 31, 2005		December 31, 2005		Increase/ Decrease	
	(Millions of Yen)	(%)	(Millions of Yen)	(%)	(Millions of Yen)	
ASSETS						
Current assets:						
Cash and cash in bank	¥54,350		¥62,064			
Accounts and notes receivable-trade	142,065		164,131			
Short-term investments	92,696		95,978			
Inventories	39,465		42,989			
Deferred tax assets	28,286		32,038			
Other current assets	9,041		11,660			
Allowance for doubtful receivables	(324)		(377)			
Total current assets	365,582	55.2	408,485	57.4	42,902	
Fixed assets:						
Property, plant and equipment						
Buildings and structures	66,970		64,857			
Machinery, equipment and vehicle	25,283		23,101			
Land	16,995		17,120			
Construction in progress	4,046		11,452			
Others	9,625	122,922	9,256	125,788	2,865	
Intangible assets		37,010		38,684	1,674	
Investments and other assets						
Investment securities	89,298		98,766			
Long-term loans receivable	112		65			
Deferred tax assets	20,572		17,675			
Other assets	28,313		23,402			
Allowance for doubtful receivables	(1,101)	137,196	(811)	139,097	1,901	
Total fixed assets		297,128		303,569	6,440	
Total		¥662,711	100.0	¥712,055	100.0	¥49,343

EISAI CO., LTD.

EISAI CO., LTD.

2-1) CONSOLIDATED STATEMENTS OF INCOME

Third Quarter of FY2004 and 2005 (Three Months Ended Dec. 31)

		(%)		(%)	Increase/ Decrease (Millions of Yen)
	¥143,442	100.0	¥167,280	100.0	¥23,838
	25,243	17.6	29,930	17.9	4,687
	118,198	82.4	137,349	82.1	19,151
Gross profit	11	0.0	42	0.0	31

EISAI CO., LTD.

2-2) CONSOLIDATED STATEMENTS OF INCOME

(Nine Months Ended Dec. 31, 2004 and 2005)

Increase
(Decrease)

EISAI CO., LTD.

3. CONSOLIDATED STATEMENTS OF CAPITAL SURPLUS/RETAINED EARNINGS

	April 1, 2004 - March 31, 2005		April 1, 2005 - December 31, 2005	
Account Title	(Millions of Yen)		(Millions of Yen)	
Capital surplus				
Capital surplus reserve, beginning balance		¥55,222		¥55,222
Capital surplus ending balance		55,222		55,222
Retained earnings, beginning balance				
Consolidated earned surplus, beginning balance		342,830		387,077
Increase in retained earnings				
- Net income		55,505		52,156
Decrease in retained earnings				
- Dividends	11,223		21,435	
- Bonuses to Directors	34			
- Loss on treasury stock	1	11,258	18	21,453
Retained earnings, ending balance		¥387,077		¥417,780

EISAI CO., LTD.

4-1) CONSOLIDATED STATEMENTS OF CASH FLOWS

Third Quarter of FY2004 and 2005 (Three Months Ended Dec. 31)

Account Title	October 1, 2004 - December 31, 2004 (Millions of Yen)	October 1, 2005 - December 31, 2005 (Millions of Yen)	Increase (Decrease) (Millions of Yen)
I. Operating activities:			
Income before income taxes and minority interests	¥25,874	¥34,353	
Depreciation and amortization	5,399	6,520	
Impairment loss	-	20	
Increase (Decrease) in allowance for doubtful receivables	46	(86)	
Interest and dividend income	(594)	(1,180)	
Interest expense	6	16	
Equity in (earnings) loss of associated companies	(3)	(7)	
Net (gain) loss on sales and disposal of fixed assets	47	38	
Provision for liability for retirement benefits	1,746	1,411	
(Gain) Loss on sales of short-term investments and investment securities	(2)	(4)	
(Gain) Loss on impairment of securities	(2)	-	
(Increase) Decrease in trade receivables	(7,056)	(21,291)	
(Increase) Decrease in inventories	(1,679)	1,394	
Increase (Decrease) in accounts payable	1,577	1,390	
Increase (Decrease) in other current liabilities	602	4,731	
Increase (Decrease) in reserve for sales rebates	3,118	(579)	
Others	(369)	(1,767)	
Sub-total	28,712	24,959	(3,753)
Interest and dividends received	566	1,149	
Interest paid	(6)	(13)	
Income taxes paid	(17,031)	(16,882)	
Net cash provided by operating activities	12,240	9,212	(3,028)
II. Investing activities:			
Purchases of short-term investments	(37)	(14)	
Proceeds from sales and redemptions of short-term investments	826	515	
Purchases of property, plant and equipment	(5,317)	(5,114)	
Proceeds from sales of property, plant and equipment	154	53	
Purchases of intangible assets	(274)	(7,106)	
Purchases of investment securities	(2,587)	(7,383)	
Proceeds from sales and redemptions of investment securities	1,304	4,202	
(Increase) Decrease in cash provided by (used in) investing activities	(8,056)	(10,099)	(2,042)
III. Financing activities:			
	(72)	(288)	
Purchase of treasury stock	(6,087)	-	
Dividends paid	(6,043)	(11,432)	
	(39)	(15)	
	(12,242)	(11,737)	504
	(2,986)	2,651	5,638
	(11,044)	(9,972)	1,072
	163,665	160,137	(3,527)
	¥152,620	¥150,165	(¥2,455)

EISAI CO., LTD.

4-2) CONSOLIDATED STATEMENTS OF CASH FLOWS

(Nine Months Ended Dec. 31, 2004 and 2005)

	April 1, 2004 - December 31, 2004	April 1, 2005 - December 31, 2005	Increase (Decrease)
Account Title	(Millions of Yen)	(Millions of Yen)	(Millions of Yen)
I. Operating activities:			
Income before income taxes and minority interests	¥69,257	¥80,996	
Depreciation and amortization	15,864	18,546	
Impairment loss		230	
Increase (Decrease) in allowance for doubtful receivables	32	(69)	
Interest and dividend income	(1,549)	(2,998)	
Interest expense	21	37	
Equity in (earnings) loss of associated companies	(18)	(0)	
Net (gain) loss on sales and disposal of fixed assets	50	279	
Provision for liability for retirement benefits	5,023	4,409	
(Gain) Loss on sales of short-term investments and investment securities	(1,145)	(5)	
(Gain) Loss on impairment of securities	61	3	
(Increase) Decrease in trade receivables	(12,197)	(18,658)	
(Increase) Decrease in inventories	(3,250)	(1,499)	
Increase (Decrease) in accounts payable	1,261	3,122	
Increase (Decrease) in other current liabilities	5,051	10,579	
Increase (Decrease) in reserve for sales rebates	9,083	(3,249)	
Others	15	(3,961)	
Sub-total	87,558	87,760	202
Interest and dividends received	1,509	2,821	
Interest paid	(20)	(29)	
Income taxes paid	(36,024)	(41,435)	
Net cash provided by operating activities	53,022	49,116	(3,905)
II. Investing activities:			
Purchases of short-term investments	(80)	(54)	
Proceeds from sales and redemptions of short-term investments	3,506	2,070	
Purchases of property, plant and equipment	(17,543)	(18,356)	
Proceeds from sales of property, plant and equipment	460	221	
Purchases of intangible assets	(12,516)	(13,244)	
Purchases of investment securities	(10,026)	(10,151)	
Proceeds from sales and redemptions of investment securities	8,448	10,391	
(Increase) Decrease in time deposits (exceeding 3 months)	(403)	(190)	
Others	(1,398)	5,078	
Net cash used in investing activities	(29,552)	(24,235)	5,317
III. Financing activities:			
Net increase (decrease) in short-term bank borrowings	560	(439)	
Purchase of treasury stock	(6,087)	-	
Dividends paid	(11,223)	(21,435)	
Dividends paid to minority interests	-	(49)	
Others	(102)	59	
Net cash used in financing activities	(16,852)	(21,864)	(5,012)
IV. Effect of exchange rate changes on cash and cash equivalents	(142)	4,719	4,861
V. Net increase (decrease) in cash and cash equivalents	6,475	7,736	1,260
VI. Cash and cash equivalents at beginning of period	146,116	142,429	(3,687)
VII. Cash and cash equivalents at beginning of period of newly consolidated subsidiaries	28	-	(28)
VIII. Cash and cash equivalents at end of period	¥152,620	¥150,165	(¥2,455)

5. SEGMENT INFORMATION

1. Business Segment Information

(1) For the third quarter, ended December 31, 2004

(Millions of Yen)

	Pharma- ceuticals	Others	Total	Eliminations and Corporate	Consolidated
I. Sales					
(1) Sales to customers	¥138,301	¥5,140	¥143,442	–	¥143,442
(2) Intersegment sales	68	3,999	4,068	(¥4,068)	–
Total sales	138,370	9,140	147,510	(4,068)	143,442
Operating expenses	111,033	8,664	119,697	(2,958)	116,739
Operating income	¥27,337	¥475	¥27,813	(¥1,109)	¥26,703

I. Sales					
(1) Sales to customers	¥161,673	¥5,607	¥167,280	–	¥167,280
(2) Intersegment sales	69	4,295	4,365	(¥4,365)	–
Total sales	161,742	9,903	171,645	(4,365)	167,280
Operating expenses	128,096	9,236	137,333	(3,002)	134,330
Operating income	¥33,646	¥666	¥34,312	(¥1,362)	¥32,949

Notes:

1. The Company classifies consolidated operations into two segments: 'Pharmaceuticals' including prescription pharmaceuticals and 'Others' which encompasses all operations other than pharmaceuticals.

2. Major products in each segment are as follows:

Business segment	Major products
Pharmaceuticals	Prescription pharmaceuticals; Consumer health care products; Diagnostic pharmaceuticals; etc.
Others	Food additives; Chemicals; Machinery; Others

(3) For the nine months, ended December 31, 2004

(Millions of Yen)

	Pharma- ceuticals	Others	Total	Eliminations and Corporate	Consolidated
--	----------------------	--------	-------	----------------------------------	--------------

3. Intersegment sales in Japan principally represent product sales from Eisai Co., Ltd. (hereinafter referred to as 'the Parent Company') to the overseas subsidiaries. Intersegment sales in North America, Europe, and Asia and Others are principally sales from the overseas subsidiaries, which manage research and development for the Parent Company.

(3) For the nine months, ended December 31, 2004

(Millions of Yen)

	Japan	North America	Europe	Asia and Others	Total	Eliminations and Corporate	Consolidated
I. Sales							
(1) Sales to customers	¥205,880	¥160,570	¥29,367	¥8,608	¥404,427	–	¥404,427
(2) Intersegment sales	48,252	15,229	5,709	17	69,208	(69,208)	–
Total sales	254,132	175,799	35,077	8,625	473,635	(69,208)	404,427
Operating expenses	195,184	165,961	32,615	6,789	400,550	(64,408)	336,141
Operating income	¥58,948	¥9,837	¥2,462	¥1,836	¥73,084	(¥4,799)	¥68,285

(4) For the nine months, ended December 31, 2005

(Millions of Yen)

(2) For the third quarter, ended December 31, 2005

Securities Code: 4523

2005.10

Reference Data

Third Quarter Ended December 31, 2005

February 2, 2006



For Inquiry:

Corporate Communications Department

TEL 81-3-3817-5120 FAX 81-3-3811-3077

<http://www.eisai.co.jp/eir/>

I. Consolidated Financial Highlights

1. Statement of Income Data

(billions of yen)

Years Ended/Ending March 31	Nine months ended Dec 31				
	2005	2006	Change %	2005	2006 (e)
Net Sales	404.4	449.9	111.2	533.0	595.0
Cost of Sales	75.7	78.7	104.0	98.5	104.0
Research and Development Expenses	57.0	67.0	117.6	78.3	94.0
Selling, General and Administrative Expenses	203.5	226.0	111.1	269.4	301.0
Operating Income	68.3	78.2	114.5	86.8	96.0
Ordinary Income	69.8	81.4	116.6	89.1	99.0
Net Income	44.1	52.2	118.4	55.5	63.0
			(Inc./Dec.)		
Earnings per Share (yen)	153.3	182.5	29.2	193.4	220.4
Dividends per Share (yen)	-	-	-	56.0	90.0

* "Cost of Sales" includes "Reversal/Provision of reserve for sales returns".

2. Balance Sheet Data

(billions of yen)

	2005		Inc./Dec.
	31-Mar	31-Dec	
Total Assets	662.7	712.1	49.3
Shareholders' Equity	459.6	505.2	45.6
Equity-to-Total Asset Ratio (%)	69.4%	71.0%	1.6%

3. Capital Expenditures and Depreciation/Amortization

(billions of yen)

Years Ended/Ending March 31	Nine months ended Dec 31				
	2005	2006	Inc./Dec.	2005	2006 (e)
Capital Expenditures	35.2	19.8	(15.4)	49.0	28.0
Property, plant and equipment	13.0	13.1	0.1	21.7	20.0
Intangible Assets	22.1	6.7	(15.4)	27.3	8.0
Depreciation/Amortization	15.9	18.5	2.7	22.4	24.0

* Depreciation/amortization includes "Property, plant and equipment" and "Intangible assets".

4. Statements of Cash Flows Data

(billions of yen)

Years Ended/Ending March 31	Nine months ended Dec 31				
	2005	2006	Inc./Dec.	2005	2006 (e)
Net cash provided by operating activities	53.0	49.1	(3.9)	49.2	
Net cash used in investing activities	(29.6)	(24.2)	5.3	(37.5)	
Net cash used in financing activities	(16.9)	(21.9)	(5.0)	(16.7)	
Cash and cash equivalents at end of period	152.6	150.2	(2.5)	142.4	
Free Cash Flow	23.4	17.7	(5.7)	10.5	

* Free Cash Flow = "Net cash provided by operating activities" - "Capital expenditures" - "Other revenue/payment for continuous activities".

II. Consolidated Statements of Income

1. Consolidated Statement of Income

(billions of yen)

Years Ended/Ending March 31							<Explanation>
	2005	Sales %	2006	Sales %	Chg. %	Inc./ Dec.	
Net sales	404.4	100.0	449.9	100.0	111.2	45.5	
Cost of sales	75.7	18.7	78.7	17.5	103.9	2.9	
Reversal of reserve for sales returns	(0.1)	(0.0)	0.0	0.0		0.1	
Gross profit	328.8	81.3	371.2	82.5	112.9	42.5	
Research and development expenses	57.0	14.1	67.0	14.9	117.6	10.0	

2. Financial Results by Business Segment

2-1. Consolidated Net Sales by Business Segment

Years Ended/Ending March 31	(billions of yen)		
	Nine months ended Dec 31		
	2005	2006	2005
Net sales to customers	404.4	449.9	533.0
Pharmaceuticals	387.7	434.0	511.0
(In-house developed products %)	89.0%	89.2%	89.1%
Japan	190.4	206.4	247.7
North America	190.4		

3. Financial Results by Geographical Area

3-1. Consolidated Net Sales by Geographical Segment

(billions of yen)

Years Ended/Ending March 31	Nine months ended Dec 31		
	2005	2006	2005
Net sales to customers	404.4	449.9	533.0
Japan	205.9	220.8	268.3
North America	160.6	183.7	214.5
Europe	29.4	32.9	38.3
Asia and others	8.6	12.6	11.9
Overseas sales	198.5	229.1	264.7
Overseas sales ratio (%)	49.1%	50.9%	49.7%

3-2. Consolidated Operating Income by Geographical Segment

(billions of yen)

Years Ended/Ending March 31	Nine months ended Dec 31		
	2005	2006	2005
Operating income/loss	68.3	78.2	86.8
Japan	58.9	63.6	74.4
North America	9.8	15.9	11.4
Europe	2.5	3.4	3.5
Asia and others	1.8	2.2	2.1
Eliminations and corporate	(4.8)	(6.9)	(4.5)

4. Overseas Sales

(billions of yen)

Years Ended/Ending March 31	Nine months ended Dec 31		
	2005	2006	2005
Net sales	404.4	449.9	533.0
Overseas sales	215.3	249.7	288.1
North America	166.6	190.5	222.8
Europe	38.4	44.9	51.2
Asia and others	10.4	14.3	14.1
Overseas sales (%)	53.2%	55.5%	54.1%

* Major areas and countries included in each category:

1. North America: The U.S. and Canada
2. Europe: The United Kingdom, France, Germany, etc.
3. Asia and Others: East Asia, South-East Asia, and South-Central America, etc.

5. Global Product Sales (Eisai Territory Sales)

5-1. ARICEPT Sales by Area

Years Ended/Ending March 31		Nine months ended Dec 31		
		2005	2006	2005
Area				
Japan	¥ Billions	27.2	32.6	35.1
U.S.	¥ Billions [US \$ Millions]	71.5 [659]	84.3 [752]	97.6 [907]
U.K.	¥ Billions [UK £ Millions]	0.7 [4]	0.8 [4]	1.0 [5]
France	¥ Billions [Euro Millions]	14.2 [106]	15.8 [115]	19.1 [141]
Germany	¥ Billions [Euro Millions]	6.2 [46]	6.0 [44]	7.1 [53]
Europe Total	¥ Billions	21.2	22.6	27.2
Asia	¥ Billions	2.1	3.1	2.9
Total	¥ Billions	122.0	142.6	162.9

* Sales forecast for Eisai sales territories for the year ending March 2006 is ¥194.0 billion.

5-2. ACIPHEX/PARIET Sales by Area

Years Ended/Ending March 31		Nine months ended Dec 31		
		2005	2006	2005
Area				
Japan	¥ Billions	14.9	21.7	19.4
U.S.	¥ Billions [US \$ Millions]	79.2 [729]	84.2 [751]	104.1 [968]
U.K.	¥ Billions [UK £ Millions]	4.3 [22]	4.1 [21]	5.5 [28]
Germany	¥ Billions [Euro Millions]	0.9 [6]	1.1 [8]	1.2 [9]
Italy	¥ Billions [Euro Millions]	- [-]	0.4 [3]	- [-]
Europe Total	¥ Billions	5.2	5.6	6.8
Asia	¥ Billions	1.5	2.5	2.1
Total	¥ Billions	100.8	114.0	132.3

* Sales forecast for Eisai sales territories for the year ending March 2006 is ¥150.0 billion.

* Sales in Italy indicate intermediate sales to Janssen in Italy.

5-3. ZONEGRAN Sales by Area

Years Ended/Ending March 31		Nine months ended Dec 31		
		2005	2006	2005
Area				
U.S.	¥ Billions [US \$ Millions]	8.2 [76]	11.2 [100]	11.1 [104]
Europe, Asia	¥ Billions	-	0.3	0.0
Total	¥ Billions	8.2	11.5	11.1

* Initiated shipping in U.K. and Germany from June 2005.

* Sales forecast for Eisai sales territories for the year ending March 2006 is ¥14.0 billion.

<Reference> [Non-consolidated]

Eisai Inc. (U.S.A.)/Pharmaceutical Sales, Production

Years Ended/Ending March 31		Nine months ended Dec 31		
		2005	2006	2005
Net sales	¥ Billions	160.8	184.7	215.0
	[US \$ Millions]	[1,481]	[1,648]	[2,001]
Operating income	¥ Billions	9.0	15.0	10.3
	[US \$ Millions]	[83]	[133]	[96]
Net income	¥ Billions	5.7	10.1	6.6
	[US \$ Millions]	[52]		



6. Selling, General and Administrative Expenses

6-1. Research and Development Expenses

(billions of yen)

Years Ended/Ending March 31	Nine months ended Dec 31			
	2005	2006	2005	2006 (e)
Net sales	404.4	449.9	533.0	595.0
Research and development expenses	57.0	67.0		

III. Consolidated Balance Sheet

1. Consolidated Balance Sheet <Assets>

						(billions of yen)		<Explanation>
31-Mar	%	31-Dec	%	Chg. %	Inc./ Dec.			
Current assets:								

2. Consolidated Balance Sheet <Liabilities and Shareholders' Equity>

	(billions of yen)						<Explanation>
	2005				Chg. %	Inc./ Dec.	
	31-Mar	%	31-Dec	%			
Current liabilities:							
Accounts payable-trade	15.7		19.9			4.3	
Short-term borrowings	0.8		0.5			(0.4)	
Accounts payable-other	45.1		50.9			5.8	
Accrued expenses	33.7		33.4			(0.3)	
Accrued income taxes	21.1		14.9			(6.2)	
Reserve for sales rebates	28.4		27.8			(0.6)	
Other reserves	0.8		0.8			0.0	
Other current liabilities	3.9		8.9			5.0	
Total current liabilities	149.6	22.6	157.2	22.0	105.1	7.6	
Long-term liabilities:							
Deferred tax liabilities	0.1		0.1			0.0	
Liabilities for retirement benefits	32.5		35.4			2.9	
Allowance for retirement of Directors	2.3		1.3			(1.0)	
Other long-term liabilities	9.7		3.7			(6.0)	
Total long-term liabilities	44.6	6.7	40.5	5.7	90.8	(4.1)	
Total liabilities	194.1	29.3	197.6	27.7	101.8	3.5	
Minority Interests	9.0	1.3	9.2	1.3	102.2	0.2	
Shareholders' equity:							
Common stock	45.0	6.8	45.0	6.3		-	
Capital surplus	55.2	8.3	55.2	7.8		-	
Retained earnings	387.1	58.4	417.8	58.7		30.7	
Net unrealized gains on available-for-sale securities	9.4	1.4	18.2	2.5		8.8	Net unrealized gains on available-for-sale securities
Foreign currency translation adjustments	(4.9)	(0.7)	1.1	0.2		6.0	<Increase Factor(s)>
Treasury stock	(32.1)	(4.8)	(32.0)	(4.5)		0.1	Appreciated market price of holding securities
Total shareholders' equity	459.6	69.4	505.2	71.0	109.9	45.6	
Total liabilities, minority interests and shareholders' equity	662.7	100.0	712.1	100.0	107.4	49.3	

IV. Consolidated Statements of Cash Flows

Years Ended/Ending March 31	(billions of yen)			<Explanation>
	2005	2006	Inc./Dec.	
Operating activities				
Income before income taxes & minority interests	69.3	81.0	11.7	
Depreciation and amortization	15.9	18.5	2.7	
Other non-cash losses/gains	5.0	4.5	(0.5)	
Operating assets/liabilities increase/decrease	1.2	(10.6)	(11.8)	
Others	(3.8)	(5.7)	(1.9)	
Subtotal	87.6	87.8	0.2	
Interest paid/received	1.5	2.8	1.3	
Cash paid for income taxes	(36.0)	(41.4)	(5.4)	
Net cash provided by operating activities	53.0	49.1	(3.9)	
Investing activities				
Capital expenditures	(30.1)	(31.6)	(1.5)	
Other revenue/payment for continuous activities	0.5	0.2	(0.2)	
Purchases/sales of securities	1.8	2.3	0.4	
Others	(1.8)	4.9	6.7	
Net cash used in investing activities	(29.6)	(24.2)	5.3	
Financing activities				
Dividends paid	(11.2)	(21.4)	(10.2)	
Short-term debt proceeds/payments	0.6	(0.4)	(1.0)	
Treasury stock purchase	(6.1)	-	6.1	
Others	(0.1)	0.0	0.1	
Net cash used in financing activities	(16.9)	(21.9)	(5.0)	
Effect of exchange rate changes on cash and cash equivalents				
Net increase in cash and cash equivalents	6.5	7.7	1.3	

V. Non-Consolidated Financial Highlights

1. Consolidated Financial Highlights

1-1. Statements of Income Data

(billions of yen)

Years Ended/Ending March 31	Nine months ended Dec 31				
	2005	2006	Change %	2005	2006 (e)
Net Sales	234.6	254.2	108.4	307.9	327.0
Cost of Sales	59.8	60.1	100.4	77.5	77.0
Research and Development Expenses	55.8	66.0	118.3	77.1	91.0
Selling, General and Administrative Expenses	65.1	71.3	109.5	85.6	94.0
Operating Income	53.8	56.8	105.6	67.6	65.0
Ordinary Income	54.8	58.3	106.3	69.1	65.0
Net Income	35.0	37.5	107.3	43.5	41.0

* "Cost of Sales" includes "Reversal/Provision of reserve for sales returns".

1-2. Balance Sheet Data

(billions of yen)

	2005		Inc./Dec.
	31-Mar	31-Dec	
Total Assets	530.6	547.4	16.8
Shareholders' Equity	431.7	456.5	24.8
Equity-to-Total Asset Ratio (%)	81.4%	83.4%	2.0%

1-3. Capital Expenditures and Depreciation/Amortization

(billions of yen)

Years Ended/Ending March 31	Nine months ended Dec 31				
	2005	2006	Inc./Dec.	2005	2006 (e)
Capital Expenditures	13.1	11.0	(2.1)	25.0	17.0
Property, plant and equipment	9.4	6.1	(3.3)	16.3	11.0
Intangible Assets	3.7	4.9	1.2	8.7	6.0
Depreciation/Amortization	9.9	12.0	2.2	14.3	16.0

* Depreciation/amortization includes "Property, plant and equipment" and "Intangible assets".

1-4. Statements of Cash Flows Data

(billions of yen)

Years Ended/Ending March 31	Nine months ended Dec 31				
	2005	2006	Inc./Dec.	2005	2006 (e)
Net cash provided by operating activities	28.8	29.9	1.1	35.0	
Net cash used in investing activities	(20.7)	(12.1)	8.6	(26.1)	
Net cash used in financing activities	(17.4)	(21.4)	(4.0)	(17.4)	
Cash and cash equivalents at end of period	78.7	76.0	(2.7)	79.5	
Free Cash Flow	12.4	14.0	1.5	11.3	

* Free Cash Flow = "Net cash provided by operating activities" - "Capital expenditures" - "Other revenue/payment for continuous activities".

2. Net Sales by Business Segment

(billions of yen)

Years Ended/Ending March 31	2005	2006	2005	2006 (e)
Net Sales	234.6	254.2	307.9	327.0
Pharmaceuticals	201.4	218.6	261.0	281.0
Prescription Pharmaceuticals(Including Exports)	187.1	204.7	242.2	262.0
(Ratio of in-house developed products to Prescription Pharmaceuticals %)				
Consumer Health Care Products	14.3	13.9	18.8	19.0
Food Additives/Chemicals, Machinery, etc.	2.6	1.4	3.1	1.5
Income from Industrial Property Rights, etc.	30.5	34.3	43.8	44.5

*Machinery business was divested and moved to a consolidated subsidiary in October 2004.

3. Exports by Geographical Area

(billions of yen)

Years Ended/Ending March 31	2005	2006	2005	2006 (e)
Net Sales	234.6	254.2	307.9	327.0
Exports	64.1	72.6	88.1	95.0
North America	46.9	50.7	64.6	-
Europe	13.8	17.9	19.0	-
Asia and Others	3.4	4.0	4.4	-
Ratio of Exports to Sales (%)	27.3%	28.6%	28.6%	29.1%

* Major areas and countries included in each category:

1. North America: The U.S. and Canada
2. Europe: The United Kingdom, France, Germany, etc.

4. Prescription Pharmaceuticals

(billions of yen)

Years Ended/Ending March 31 / Description	2005	2006	Change %	2005	2006 (e)
Alzheimer's disease treatment <i>ARICEPT</i>	27.2	32.6	119.6	35.1	43.0
Peripheral neuropathy treatment <i>METHYCOBAL</i>	24.1	24.9	103.6	30.9	32.0
Proton pump inhibitor <i>PARIET</i>	14.9	21.7	145.1	19.4	30.0
Gastritis/gastric ulcer medication <i>SELBEX</i>	17.6	16.9	96.2	22.7	22.0
Non-ionic contrast medium <i>IOMERON</i>	7.0	6.9	98.6	8.9	9.0
Muscle relaxant <i>MYONAL</i>	6.7	6.7	99.9	8.5	8.0
Osteoporosis treatment <i>GLAKAY</i>	7.1	6.7	93.8	9.0	9.0
Endoscopic examination/hypoglycemia treatment <i>GLUCAGON G NOVO</i>	3.4	3.5	103.3	4.2	4.0
Long-acting isosorbide dinitrate <i>NITOROL-R</i>	3.8	3.5	91.7	4.8	5.0
Osteoporosis treatment <i>ACONEL</i>	-	2.6	-	-	4.0
Long-actin					

7. Selling, General and Administrative Expenses (including R&D expenses)

7-1. Research and Development Expenses (R&D expenses)

(billions of yen)

Years Ended/Ending March 31	Nine Month Ended Dec 31			
	2005	2006	2005	2006 (e)
Net sales	234.6	254.2	307.9	327.0
Research and development expenses	55.8	66.0	77.1	91.0
Overseas research and development expenses	22.5	29.5	31.2	-
(Ratio of overseas R&D expenses to total R&D expenses %)	40.3%	44.7%	40.5%	-
Percentage of sales (%)	23.8%	26.0%	25.0%	27.8%

7-2. Selling, General and Administrative Expenses (SG&A expenses)

(billions of yen)

Years Ended/Ending March 31	Nine Month Ended Dec 31			
	2005	2006	2005	2006 (e)
Net sales	234.6	254.2	307.9	327.0
Selling, general and administrative expenses	65.1	71.3	85.6	94.0
Personnel expenses	26.7	25.9	35.4	-
Marketing expenses	25.4	27.8	32.8	-
Administrative expenses and others	13.0	17.6	17.5	-
Percentage of sales (%)	27.8%	28.0%	27.8%	28.7%

7-3. Selling, General and Administrative Expenses (including R&D expenses)

(billions of yen)

Years Ended/Ending March 31	Nine Month Ended Dec 31			
	2005	2006	2005	2006 (e)
Net sales	234.6	254.2	307.9	327.0
Selling, general and administrative expenses (including R&D)	120.9	137.3	162.8	185.0
Percentage of sales (%)	51.6%	54.0%	52.9%	56.6%

8. Balance Sheet Data

<Assets>

(billions of yen)

	2005		Inc./ Dec.
	31-Mar	31-Dec	
Current assets	249.3	263.7	14.5
Fixed assets	281.3	283.7	2.3
Property, plant and equipment	84.1	81.1	(3.0)
Intangible assets	17.8	19.3	1.4
Investments and other assets	179.4	183.3	3.9
Total assets	530.6	547.4	16.8

<Liabilities and Shareholders' Equity>

(billions of yen)

	2005		Inc./ Dec.
	31-Mar	31-Dec	
Current liabilities	67.9	58.1	(9.8)
Long-term liabilities	30.9	32.8	1.8
Total liabilities	98.9	90.9	(8.0)
Shareholders' equity	431.7	456.5	24.8
Total liabilities, minority interests and shareholders' equity	530.6	547.4	16.8

9. Statements of Cash Flows

(billions of yen)

Years Ended/Ending March 31	2005	2006	Inc./ Dec.
Income before income taxes & minority interests	54.2	58.2	3.9
Depreciation and amortization	9.9	12.0	2.2
Other non-cash losses/gains	4.6	3.9	(0.7)
Operating assets/liability increase/decrease	(7.7)	(11.8)	(4.1)
Others	(5.1)	(3.4)	1.7
Subtotal	55.9	58.9	3.0
Interest paid/received	0.8	1.3	0.5
Income taxes paid	(27.9)	(30.3)	(2.4)
Net cash provided by operating activities	28.8	29.9	1.1
Investing activities			
Capital expenditures	(16.8)	(16.2)	0.7
Other revenue/payment for continuous activities	0.4	0.2	(0.2)
Purchases/sales of securities	1.0	1.3	

3. Capital Expenditures and Depreciation/Amortization [Consolidated]

(billions of yen)

Years Ended/Ending March 31	2005				2006		
	First Quarter	Second Quarter	Third Quarter	Fourth Quarter	First Quarter	Second Quarter	Third Quarter
Capital expenditures	23.2	8.2	3.8	13.8	4.6	9.4	5.9
Property, plant and equipment	3.2	6.5	3.3	8.7	3.6	5.3	4.2
Intangible assets	19.9	1.7	0.5	5.1	1.0	4.0	1.7
Depreciation/Amortization	5.1	5.4	5.4	6.6	5.9	6.1	6.5

* Depreciation/amortization includes "Property, plant and equipment" and "Intangible assets".

4. Cash Flows Data [Consolidated]

(billions of yen)

Years Ended/Ending March 31	2005				2006		
	First Quarter	Second Quarter	Third Quarter	Fourth Quarter	First Quarter	Second Quarter	Third Quarter
Net cash provided by operating activities	9.4	31.4	12.2	(3.8)	12.1	27.8	9.2
Net cash used in investing activities	(18.7)	(2.8)	(8.1)	(8.0)	(8.9)	(5.3)	(10.1)
Net cash used in financing activities	(5.0)	0.4	(12.2)	0.1	(10.1)	(0.0)	(11.7)
Effect of exchange rate changes on cash and cash equivalent	133.2	163.7	152.6	142.4	136.5	160.1	150.2
Free cash flow	(8.9)	25.5	6.8	(13.0)	1.3	19.4	(3.0)

* Free Cash Flow = "Net cash provided by operating activities" - "Capital expenditures" - "Other revenue/payment for continuous activities".

5. *ARICEPT* Sales by Area (Eisai Territory Sales) [Consolidated]

Years Ended/Ending March 31

Japan

7. ZONEGRAN Sales by Area (Eisai Territory Sales) [Consolidated]

Years Ended/Ending March 31

U.S	¥ Billions	2.5	3.6	2.1	2.9	3.6	3.9	3.7
	[US \$ Millions]	[23]	[33]	[20]	[28]	[33]	[35]	[32]
Europe, Asia	¥ Billions	-	-	-	0.0	0.0	0.1	0.1
Total	¥ Billions	2.5	3.6	2.1	2.9	3.6	4.0	3.9

8. Eisai Inc. (U.S.A.)

Years Ended/Ending March 31

Net sales	¥ Billions	45.9	57.2	57.7	54.4	52.9	61.8	70.1
-----------	------------	------	------	------	------	------	------	-------------

9. Statement of Income Data [Non-Consolidated]

(billions of yen)

Years Ended/Ending March 31	2005				2006		
	First Quarter	Second Quarter	Third Quarter	Fourth Quarter	First Quarter	Second Quarter	Third Quarter
Net sales	74.8	76.5	83.3	73.4	79.0	81.9	93.3
Cost of sales	19.5	19.9	20.5	17.7	19.0	18.9	22.2
Research and development expenses	17.6	18.9	19.3	21.3	19.6	24.3	22.1
Selling, general and administrative expenses	21.0	21.5	22.6	20.5	22.9	23.4	25.0
Operating income	16.6	16.2	20.9	13.8	17.5	15.3	24.0
Ordinary income	17.4	16.7	20.7	14.3	18.1	15.6	24.6
Net income	11.3	10.8	12.9	8.5	11.6	10.1	15.9

* "Cost of Sales" includes "Reversal/Provision of reserve for sales returns".

10. Prescription Pharmaceuticals [Non-Consolidated]

(billions of yen)

Years Ended/Ending March 31	2005				2006		
	First Quarter	Second Quarter	Third Quarter	Fourth Quarter	First Quarter	Second Quarter	Third Quarter
<i>ARICEPT</i>	8.9	8.4	9.9	7.9	9.9	10.6	12.1
<i>METHYCOBAL</i>	7.7	8.0	8.4	6.8	7.8	8.2	8.9
<i>PARIET</i>	3.2	5.1	6.6	4.5	6.3	6.8	8.5
<i>SELBEX</i>	5.8	5.7	6.1	5.1	5.4	5.5	6.0
<i>IOMERON</i>	2.3	2.2	2.5	1.9	2.2	2.2	2.5
<i>MYONAL</i>	2.2	2.2	2.3	1.8	2.2	2.2	2.4
<i>GLAKAY</i>	2.4	2.3	2.4	1.9	2.2	2.2	2.3
<i>GLUCAGON G NOVO</i>	1.1	1.1	1.2	0.8	1.1	1.1	1.3
<i>NITOROL-R</i>	1.3	1.2	1.3	1.0	1.2	1.1	1.2
<i>ACTONEL</i>	-	-	-	-	-	-	2.6
<i>RULID</i>	0.7	0.6	0.9	0.7	0.7	0.6	0.8
<i>AZEPTIN</i>	0.8	0.6	0.9	1.4	0.8	0.5	0.7
Others	11.9	11.1	13.0	10.1	11.2	11.1	12.7
Prescription Pharmaceuticals Total	48.4	48.6	55.4	43.9	50.9	52.2	62.0

* Statistical segmentation of "Prescription Pharmaceutical" has been modified for the year ending March 31, 2006. Past data have been reclassified to reflect the new segmentation.

* Marketing rights of "Actonel" have been transferred from Aventis Pharma to Eisai from October 1, 2005.

11. Exports by Products [Non-Consolidated]

(billions of yen)

Years Ended/Ending March 31

Product

<i>ARICEPT</i>	5.7	5.5	4.7	5.1	6.3	4.8	6.1
<i>ACIPHEX/PARIET</i>	6.0	4.7	5.9	5.4	6.1	7.0	6.2
Others	0.7	0.7	0.8	0.7	1.2	1.0	0.9
Exports Total	12.4	10.9	11.4	11.2	13.6	12.8	13.2

* Statistical segmentation of "Prescription Pharmaceutical" has been modified for the year ending March 31, 2006. Past data have been reclassified to reflect the new segmentation and table name has changed from "Drug Substance/Bulk Tablets Sales" to "Exports by Products".

VII. Major R&D Pipeline Candidates

Ongoing and recent developments from October 2005

1. Notification of the completion of the mutual recognition procedure in the 12 EU countries for Aricept orodispersible tablet (ODT) was received.
2. Application of Aricept for the additional indication of severe dementia due to Alzheimer's disease was submitted in Japan.
3. Application of D2E7 for the indication of rheumatoid arthritis was submitted in Japan.
4. Phase III of E2007 for Parkinson's disease was initiated in the EU.
5. Phase II of E7389 for breast cancer for sub part H application was initiated in the EU/U.S.
6. Phase II of E7070 for gastric cancer was initiated in Japan.
7. Phase II of lomeron for the additional dosage and administration was initiated in Japan.
8. Application of Aricept for the additional indication of severe dementia due to Alzheimer's disease was resubmitted to the FDA.
9. Application of the anti-epilepsy drug rufinamide was resubmitted to the FDA.
10. E5564 clinical development for endotoxin-related complications after coronary artery bypass graft surgery was discontinued in the EU/U.S.

1. International Development

1-1. Approved


(Product) Name (Research Code)	Area	Date	Description	Form.	Origin
ARICEPT (E2020)	U.K.	May-05	Orodispersible Tablet (ODT)	ODT	In-house
(Additional formulation)	EU	Dec-05	Currently available in tablet form. Patients who have difficulty swallowing may find ODT more easy to swallow. Confirmation that Aricept ODT completed the mutual recognition procedure, based upon the UK national license, in the 12 EU countries was received.		

1-2. Filed for Approval

(Product) Name (Research Code)	Area	Date	Description	Form.	Origin
ARICEPT (E2020)	U.S.	Sep-02	Vascular Dementia	Tab.	In-house
(Additional indication)	(EU)		Currently indicated for the treatment of mild to moderate dementia due to Alzheimer's disease. Filed for the additional indication of vascular dementia in the U.S. Though filing for vascular dementia was withdrawn in the EU, Eisai will resubmit application once additional supportive data have been obtained.		
ARICEPT (E2020)	EU	May-04	Liquid Formulation	Liquid	In-house
			Currently available in tablet form. Filed for liquid formulation. Patients who have		

1-3. Phase III

(Product) Name (Research Code)	Area
-----------------------------------	------



2. Development in Japan

2-1. Filed for Approval

(Product) Name (Research Code)	Application	Description	Form.	Origin
T-614	Sep-03	Rheumatoid Arthritis (generic name: iguratimod) Suppresses lymphocyte proliferation, immunoglobulin production and production of inflammatory cytokines. Expected to treat chronic rheumatoid arthritis.	Tab.	Toyama Chemical
TAMBOCOR (E0735) (Additional indication)	Dec-04	Paroxysmal Atrial Fibrillation/Flutter The compound has already been approved as a treatment for ventricular tachyarrhythmias in Japan and is filed for the treatment of sporadic atrial fibrillation/flutter.	Tab.	3M
PARIET (E3810) (Additional indication)	Mar-05	Eradication of <i>H. pylori</i> in Combination with Antibiotics Currently indicated for the treatment of peptic ulcers, erosive GERD, Zollinger-Ellison syndrome in Japan. Submitted for the eradication of <i>H. pylori</i> infections.	Tab.	In-house
ARICEPT (E2020) (Additional indication)	Dec-05	Severe Dementia due to Alzheimer's disease Currently indicated for the treatment of mild to moderate dementia due to Alzheimer's disease. Submitted for treatment of severe dementia due to Alzheimer's disease.	Tab.	In-house
D2E7	Dec-05	Rheumatoid Arthritis/Human Anti TNF-alpha Monoclonal Antibody (generic name: adalimumab) By blocking the activity of Tumor Necrosis Factor- alpha (TNF-alpha) which plays a central role in inflammation in autoimmune diseases, D2E7 is expected to be effective in patients with rheumatoid arthritis(RA). Submitted for D2E7 for RA.	Inj.	Abbott

2-2. Phase III

(Product) Name (Research Code)	Expected Application	Description	Form.	Origin
PARIET (E3810) (Additional indication)	FY2005	Symptomatic GERD Currently indicated for the treatment of peptic ulcers, erosive GERD, Zollinger-Ellison syndrome in Japan. Now in Phase III for the treatment of symptomatic GERD.	Tab.	In-house
KES524	FY2007	Obesity Management/Central Acting Serotonin & Noradrenaline Reuptake Inhibitor (generic name: sibutramine) Inhibits the reuptake of the cerebral neurotransmitters noradrenaline and serotonin, enhancing the feeling of satiety and increasing energy consumption resulting in loss of body weight. Phase III in progress.	Cap.	Abbott

2-3. Phase II

(Product) Name (Research Code)	Description	Form.	Origin
E2014	Cervical Dystonia/Botulinum Toxin Type B Botulinum toxin acts on cholinergic nerve ending synapses and inhibits the release of acetylcholine to relax muscles.	Inj.	Solstice Neuro- Science
E0167	Recurrence of Hepatocellular Carcinoma/Vitamin K ₂ Vitamin K ₂ (menatetrenone) currently indicated for the treatment of osteoporosis. Now in Phase II for the prevention of recurrence of hepatocellular carcinoma.	Cap.	In-house
D2E7	Psoriasis/Human Anti TNF-alpha Monoclonal Antibody (generic name: adalimumab) By blocking the activity of Tumor Necrosis Factor- alpha (TNF-alpha) which plays a central role in inflammation in autoimmune diseases, D2E7 is expected to be effective in patients with psoriasis. Currently submitted for rheumatoid arthritis. Now in Phase II for psoriasis.	Inj.	Abbott
E7070	Anti-cancer/Cell Cycle G1 Phase Targeting Agent (generic name: indisulam) The compound induces apoptosis by inhibiting cell cycle progression in the G1 phase. Phase II for gastric cancer with a novel mechanism of action was initiated.	Inj.	In-house
Iomeron(E7337) (Additional dosage and administration)	X-ray Contrast Medium Currently indicated for CT(computed tomography) angiography. Additional dosage and administration for CT angiography is expected.	Inj.	Bracco
E7210 (Suspended)	Ultrasonic Contrast Medium Microbubbles of E7210 reflect ultrasound. Microbubbles do not disappear easily, thereby stable imaging is expected.	Inj.	Bracco

VIII. Major Events

Date	Description
Feb. 2006	Notice Concerning Revision of Year End Dividend Forecast For Fiscal Year Period (94th Company Fiscal Period) Ending March 2006 <Feb. 2, 2006 released>
Jan. 2006	Establishes a European strategic business hub in the U.K.<Jan. 24, 2006 released> Legal Action taken against Generic Products of Eisai's Selbex Capsule 50mg based on the Japanese Unfair Competition Prevention Law in the Japanese Market. <Jan. 13, 2006 released> E5564 clinical development for endotoxin-related complications after coronary artery bypass graft surgery was discontinued in the EU/U.S.
Dec. 2005	Received confirmation that Aricept, Orodispersible Tablet has successfully completed the Mutual Recognition Procedure in the 12 EU countries <Dec. 27, 2005 released> New Drug Application for Rheumatoid Arthritis Drug Adalimumab (D2E7) Submitted in Japan <Dec. 26, 2005 released> Applied for a new indication of Severe Alzheimer's disease for Aricept in Japan <Dec. 22, 2005 released> Resubmitted the sNDA Application for Aricept for Treatment of Severe Alzheimer's Disease <December 19, 2005 released> Presented Phase II Data on E7389, a Potential New Therapy for the treatment of Breast Cancer, in US Conference <Dec. 12, 2005 released> Commenced U.S. Legal Action over Aricept ANDA Filing <Dec. 8, 2005 released>
Nov. 2005	Termination of Marketing Alliance on Rulid Tablets 150mg <November 25, 2005 released> Eisai Resubmits NDA Application for the Anti-epilepsy Drug Rufinamide <Nov. 18, 2005 released> SELBELLE Tablets Launched by Eisai Medication that Improves Stomach Function by Protecting Gastric Mucosa from Stomach Acid <November 1, 2005 released>
Oct. 2005	Licensed E6020 Vaccine Adjuvant to Sanofi Pasteur SA <Oct. 28, 2005 released> Announced the sNDA application for Aricept for the treatment of severe Alzheimer's disease in the U.S. <Oct. 28, 2005 released> Eisai and TorreyPines Therapeutics entered into a new alliance contract regarding a new genetic research program for Alzheimer's disease <Oct. 11, 2005 released> E3620 for gastrointestinal motility disorders was discontinued
Sep. 2005	Dainippon Pharmaceutical (currently Dainippon Sumitomo Pharma) and Eisai signed worldwide licensing agreement outside Japan for a potential new treatment for diabetic complication <Sept. 29, 2005 released> Exclusive in-license of all U.S. promotional rights for Fragmin, an injectable anti-clotting agent <Sept. 28, 2005 released> Lost hard disk drive containing personal information in Japan <Sept. 22, 2005 released> Submitted new drug application for the anti-epileptic agent Rufinamide in the U.S. <Sept. 13, 2005 released> Changed of the distribution company from Aventis Pharma to Eisai for "Actonel 2.5mg Tablets" of Ajinomoto in Japan <Sept. 12, 2005 released> Subsidiary in India launched Aricept(donepezil HCl) and Parit(rabeprazole sodium) Sanko Junyaku and Eisai initiated co-promoting Yamasa Corporation's diagnostic kit for interstitial pneumonia,

Date	Description
Aug. 2005	<p>Submitted application to FDA for Aricept for treatment of severe Alzheimer's disease <Sept. 1, 2005 released></p> <p>Successful results in a Phase II study of E5564 (eritoran) for treatment of severe sepsis <Aug. 29, 2005 released></p> <p>Strategic alliance with BioArctic Neuroscience to develop immunotherapy for Alzheimer's disease <Aug. 26, 2005 released></p> <p>Launch of antiasthmatic, antitussive and expectorant, "Asthphyllin S" tablets in Japan <Aug. 22, 2005 released></p>
Jul. 2005	<p>Approval of Cleactor for pulmonary embolism in Japan <Aug. 2, 2005 released></p> <p>Establishment of a pharmaceuticals marketing subsidiary in Sweden <Jul 14, 2005 released></p> <p>Concerning stock options (stock acquisition rights) including the amount paid in upon the exercise of stock options <Jul 1, 2005 released></p>
Jun. 2005	<p>Launch of Zonegran(zonisamide), treatment for epilepsy In the U.K. and Germany <Jun. 27, 2005 released></p> <p>Allotment of stock options (stock acquisition rights) <Jun 24, 2005 released></p> <p>Establishment of a pharmaceuticals marketing subsidiary in Switzerland <Jun 9, 2005 released></p> <p>Cleactor for cerebral embolism was discontinued in Japan</p> <p>Aricept orodispersible tablet (ODT) was launched in the U.S.</p>
May 2005	<p>Concerning theft of a computer of Eisai's subsidiary Sanko Junyaku containing personal information <May 30, 2005 released></p> <p>Marketing authorization approval for Aricept Evess, orodispersible tablet in the U.K. <May 24, 2005 released></p> <p>Providing stock options in the form of new stock issuance <May 16, 2005 released></p>
Apr. 2005	<p>Eisai and Abbott signed a joint development agreement for new indication, psoriasis, of anti-rheumatic agent D2E7 (adalimumab) in Japan <Apr 11, 2005 released></p> <p>The merger of two subsidiaries in Taiwan <Apr. 1, 2005 released></p>

* Events are posted in accordance with execution date.